1. Barbeau A, Mars H, Botez M I, Joubert M (1971) Amantadine — HCl (Symmetrel) in the management of Parkinson’s disease. Double-blind cross-over study. Can Med Assoc 105: 42–46
2. Beasly BL, Nutr JG, Davenport RW, Chase TN (1980) Treatment with tryptophan of levodopa-associated psychiatric disturbances. Arch Neurol 37: 155–156
3. Bianchine JR, Sunyapridakul L (1973) Interactions between levodopa and other drugs: significance in the treatment of Parkinson’s disease. Drugs 6: 364–388
4. Birkmayer W, Riederer P (1985) Die Parkinsonkrankheit. Biochemie, Klinik, Therapie, 2. Aufl. Springer, Wien New York, S 36–48
5. Birkmyer W, Knoll J, Riederer P, Youdim MBH, Hars V, Marton J (1985) Increased life expectancy resulting from addition of L-Deprenyl to Madopar® treatment in Parkinson’s disease: a long-term study. J Neural Transm 64: 113–127